在相关指数中，恒生生物科技指数（HSBIO.HI）以"高纯度"和稀缺性凸显配置价值。指数精选30家纳 入港股通、市值领先的生物科技公司，覆盖18A规则上市的龙头企业，剔除传统制药，集中布局小核 酸、双抗、细胞治疗等A股相对稀缺的前沿技术平台，AH股重合度小于20%，具有差异化配置价值。指 数成分股100%属于医疗保健业，前十大权重股占比约70%，网罗药明生物、百济神州、信达生物等生 物技术和药品龙头。业绩表现高弹性，截至1月29日，恒生生物科技指数近一年涨幅达82.2%，显著跑 赢医疗医药板块同类指数。 为便利投资者高效布局港股生物科技核心资产，广发基金于2月2日至6日推出广发恒生生物科技ETF （场内简称：恒生生物科技ETF广发，代码：159169）。该ETF支持T+0交易，无QDII额度限制，低门 槛更便捷，整体费率在同类跨境ETF中处于低档位。随着生物科技景气度回升、港股流动性优势显现， 恒生生物科技ETF有望助力投资者高效把握中国生科企业在全球化进程中的结构性机遇。 近年来，生物科技产业加速发展，已成为全球科技革命与产业升级的重要方向。创新药作为行业核心引 擎，与"健康中国"战略高度契合，也是培育新质 ...

Market Overview - The Hang Seng Index reached a four-year high last week, but experienced a technical pullback due to a hawkish Federal Reserve chair nomination, indicating a risk-off sentiment in global equity markets [1] - The market sentiment index moved from panic to optimism within 16 days, suggesting a shift in investor sentiment [1] - Current market volatility is expected to persist, but it is more likely to be a correction rather than a reversal of market performance [1] Earnings and Revenue Expectations - Non-financial earnings expectations have been revised upward by 0.4% over the past four weeks, while revenue expectations have been slightly downgraded by 0.1% [2] - The sectors with the most significant upward revisions in earnings expectations include non-ferrous metals (7.7%), military industry (4.0%), and electric new energy (1.8%) [2] Capital Flow - Foreign capital continues to flow into Hong Kong stocks, with net inflows reaching $2.8 billion, up from $1.95 billion the previous week [3] - Active foreign capital has seen a continuous inflow for three weeks, with a record weekly inflow of $640 million [3] - The nomination of Kevin Warsh as the next Federal Reserve chair has led to short-term volatility, but the medium-term liquidity outlook remains accommodative [3] Market Sentiment - The market sentiment index has risen to 62.1, indicating an optimistic outlook [4] - Factors contributing to this optimism include strong net inflows from southbound capital and high buying intensity [4] Investment Recommendations - Companies with earnings certainty should be considered as core holdings, while opportunities to increase allocations in technology and cyclical materials should be explored during market corrections [5] - Focus on sectors showing upward trends, such as AI-related industries, semiconductor manufacturing, and innovative pharmaceuticals [5]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

很多人至今还在问：坐拥几千亿，身边围着全世界最聪明的脑袋和最尖端的药，怎么就换不回一条命？ 这恰恰是赵宁留给世人最硬核的最后一课，在生物学的铁壁面前，钞票有时候真的只是一堆纸。 2023年温州女首富抗癌失败，即使名下有两家医药上市公司，市值高达3700亿元，最后还是拯救不了自 己。 站在2026年1月的凛冽寒风里，回望三年前的那个初夏，你会发现那是一个极其充满张力的时刻。 2023年5月，两块屏幕上的画面构成了最残酷的蒙太奇。一块屏幕上，药明康德与药明生物的市值红线 狂舞，那个数字最终定格在惊人的3700亿元。这庞大的商业帝国掌控着全球95%顶尖药企的研发命脉。 而在另一块心电监护仪的屏幕上，57岁的赵宁，这条红线被拉成了无限延长的直线。这位帝国的缔造者 之一、温州女首富，在与癌症死磕了整整20年后，还是没能跑赢死神。 这不仅仅是一则富豪讣告，这是一个关于"药神"救不了自己，却无意间救了时代的悲剧。 但这堆"纸"并非毫无意义，要读懂它的重量，我们得把时钟拨回到千禧年。 那时候的赵宁和李革，刚从哥伦比亚大学拿到博士学位，在美国的大药企里混得风生水起。2000年，两 口子受邀回北大演讲，这一趟回国，直接把他们的" ...

恒生医疗低开低走大跳水，截至收盘下跌2.54%。石药集团大跌10.2%，药明康德下跌3.81%，中国生物 下跌3.35%，三生制药、药明生物等多股跌幅在2%上方。 恒生银行低开低走终结四连涨，截至收盘下跌1.63%。建设银行大跌3.06%，民生银行、重庆农村商业 银行、农业银行、交通银行、工商银行等近10只个股跌幅在2%上方。 低开低走后全天震荡下行，截至收盘恒生指数大跌2.08%。恒生医疗跌幅居前，大消费、互联网、银行 等紧随其后。 大消费低开低走大跳水，截至收盘下跌2.21%。周大福下跌6.74%，吉利汽车下跌4.23%，比亚迪股份、 农夫山泉、泡泡玛特、安踏体验、百威亚大等超10只个股跌幅在3%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Core Viewpoint - China Galaxy Securities is optimistic about the pharmaceutical industry's investment opportunities in 2026, focusing on hard technology in medicine, innovation, and overseas expansion, while seeking alpha in niche segments [1] Group 1: Investment Trends - In Q4 2025, public fund holdings in pharmaceuticals decreased, indicating an overall low allocation level [1] - The market value of pharmaceutical theme funds decreased by 9.73% to 205.9 billion yuan, which is 66.54% higher than the average since 2019 [1] - The market value of the pharmaceutical biotechnology sector fell by 18.81% to 312.5 billion yuan, with a holding ratio of 8.12%, below the historical average by 3.89 percentage points [1] Group 2: Stock Performance - The top five pharmaceutical stocks held by public funds in Q4 2025 saw significant reductions in both the number of funds and total market value, with notable declines in stocks like Heng Rui Medicine and WuXi AppTec [2] - The concentration of holdings has shifted from innovative drugs to medical devices and services, indicating a change in market investment focus [2] Group 3: Industry Data Overview - The pharmaceutical manufacturing industry's revenue has shown a slight decline, with a year-on-year decrease of 1.2% in Q4 2025 [3] - Medical service volumes remained stable, with a total of 1.86 billion outpatient visits in early 2025, reflecting a 0.1% year-on-year decrease [3] - The overall operation of the medical insurance fund has been stable, with total income of 2.632 trillion yuan and total expenditure of 2.110 trillion yuan from January to November 2025 [3] Group 4: Market Comparison - The pharmaceutical industry has underperformed compared to the CSI 300 index, with a rolling P/E ratio of 38.19 compared to 14.14 for the CSI 300, indicating a premium of 170.14% over the index [3] - The SW pharmaceutical biotechnology index increased by 1.44% from early 2024 to January 28, 2026, while the CSI 300 rose by 37.15%, showing a relative underperformance of 35.71% for the pharmaceutical sector [3]

SND006系生诺医药自主研发、享有全球权益的双特异性抗体，拟用于治疗炎症性肠病（IBD）等自身 免疫性疾病，目前已完成体外功能验证研究。生诺医药计划2026年向中国国家药品监督管理局 （NMPA）和美国食品药品监督管理局（FDA）提交新药临床试验申请（IND）。 1月29日，药明生物与生诺医药共同宣布，双方就创新双特异性抗体SND006的工艺开发和生产达成战略 合作。根据双方签署的协议，生诺医药将借助药明生物在生物药开发和生产领域积累的丰富经验和规模 化生产能力，推进SND006的临床前药学研究和临床样品制备，加速临床申报进程。 （药明生物公众号） ...

0:00 据药明生物官微，药明生物与生诺医药1月29日共同宣布，双方就创新双特异性抗体SND006的工艺开发 和生产达成战略合作。SND006拟用于治疗炎症性肠病（IBD）等自身免疫性疾病。 ...

Industry Overview - The pharmaceutical and biotechnology sector experienced a decline of 0.39% last week, ranking 27th among 31 primary industries in the Shenwan index. The CSI 300 index fell by 0.62%, indicating that the pharmaceutical sector outperformed the CSI 300 by 0.23 percentage points [3] - The medical services sub-sector reported a drop of 2.17%, while other sub-sectors such as traditional Chinese medicine and medical commercial showed positive growth [3] Company Performance - Notable performers in the medical services sector included: - Nuohe Zhiyuan (+11.5%) - Xin Licheng (+9.4%) - Dian Diagnostics (+8.2%) - ST Zhongzhu (+7.1%) - Guangzheng Eye Hospital (+6.2%) - Underperformers included: - Boteng Co. (-6.9%) - Chengda Pharmaceutical (-6.6%) - WuXi AppTec (-6.4%) - Mediso (-4.8%) - Chengdu Xian Dao (-4.5%) [4] Financial Metrics - The medical services sector's Price-to-Earnings (PE) ratio is 35.30X, with a one-year maximum of 41.13X and a minimum of 28.46X. The Price-to-Book (PB) ratio stands at 3.58X, with a one-year maximum of 4.00X and a minimum of 2.48X. The PE ratio decreased by 0.85X and the PB ratio decreased by 0.09X compared to the previous week [6] CXO Industry Insights - The J.P. Morgan Healthcare Conference highlighted an optimistic outlook for the CXO industry, with companies like WuXi AppTec and WuXi Biologics showcasing strong growth prospects. The industry is transitioning from scale competition to value competition, focusing on advanced technologies and global supply chains. Notably, ADC CDMO is expected to drive significant revenue growth [7] Investment Recommendations - The report maintains a "buy" rating for the medical services sector, emphasizing the importance of innovation in the pharmaceutical supply chain. Key areas of focus include: - High growth: Companies involved in ADC CDMO and peptide CDMO, such as WuXi AppTec and Hao Yuan Pharmaceutical - Expected improvement: Third-party testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry, such as Aier Eye Hospital and Dian Diagnostics [8]

Investment Rating - The report maintains a positive investment rating for the CXO industry, highlighting strong recovery and growth potential through 2026 [7][41]. Core Insights - The global CXO industry is experiencing a robust recovery, with significant performance from leading companies, and is expected to maintain high levels of activity into 2026 [1]. - Biotech financing reached a historical high in Q4 2025, indicating a rebound in demand from multinational pharmaceutical companies [7]. - The Chinese market is showing vitality in innovative drug development, with a 19% year-on-year increase in IND applications [7]. Summary by Sections 1. Global CXO Industry Recovery - The CXO industry is set for a strong recovery, with leading companies like WuXi AppTec showing impressive growth, projecting a revenue of 45.5 billion yuan in 2025, a year-on-year increase of 15.8% [10]. - WuXi AppTec's TIDES business is expected to grow over 90% in revenue, with a significant increase in production capacity [10]. - The number of IND applications in China reached 2,703 in 2025, a 19% increase from the previous year, indicating a growing clinical pipeline [26]. 2. Company-Specific Insights - **WuXi Biologics**: The company signed 209 new projects in 2025, with a total of 945 projects, reflecting a 16% year-on-year increase. The demand for new technology platforms is driving growth [15]. - **WuXi AppTec**: The company is expected to see a revenue growth of over 45% in 2025, with a focus on ADC and XDC projects, and a global market share increase to over 24% [18]. - **Tigermed**: The company is benefiting from a recovery in the CRO market, with a projected market size of 52.5 billion yuan in 2025 and a stable client structure [25]. 3. Investment Recommendations - For CRO, the report recommends focusing on leading platforms like Tigermed and specialized companies such as Huanbo and Zhaoyan [41]. - In the CDMO sector, it suggests investing in companies with strong positions in peptide supply chains and ADC trends, including WuXi AppTec and Huyuan Biotech [41].